{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:30:25Z","timestamp":1770701425007,"version":"3.49.0"},"reference-count":48,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,1,21]],"date-time":"2010-01-21T00:00:00Z","timestamp":1264032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Loss of B\u2010cell tolerance is a hallmark feature of the pathogenesis in systemic lupus erythematosus (SLE), an autoimmune disease that is characterized by hypergammaglobulinemia and autoantibody production. These autoantibodies lead to formation of immune\u2010complex deposition in internal organs causing inflammation and damage. Autoreactive B\u2010cells are believed to be central in the pathophysiology of SLE. Other than its role in the production of antibodies that mediate humoral immune response, B\u2010cells also function as antigen\u2010presenting cells and are capable of activating T\u2010cells. Activated B\u2010cells may also produce pro\u2010inflammatory cytokines that aggravate local inflammation. Abnormal B\u2010cell homeostasis has been described in SLE patients. This may occur as a result of intrinsic B\u2010cell defect or from aberrant regulation by maturation and survival signals. B\u2010cell\u2010based therapy is the current mainstream of research and development of novel therapies in SLE patients with severe and refractory disease. Potential cellular and molecular targets for B\u2010cell therapies include cell surface molecules such as CD20 (rituximab) and CD22 (epratuzumab); co\u2010stimulatory molecules involved in B\u2010cell\u2013T\u2010cell interaction such as CTLA4 and B7 molecules (abatacept); maturation and growth factors such as B\u2010cell activating factor and a proliferation\u2010inducing ligand (belimumab, briobacept, atacicept) and B\u2010cell tolerogen (abetimus). This article provides an overview on normal B\u2010cell physiology and abnormal B\u2010cell biology in SLE that form the immunological basis of B\u2010cell\u2010targeted therapy in the treatment of these patients with refractory diseases.<\/jats:p>","DOI":"10.1111\/j.1756-185x.2009.01458.x","type":"journal-article","created":{"date-parts":[[2010,1,21]],"date-time":"2010-01-21T07:22:12Z","timestamp":1264058532000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The immunological basis of B\u2010cell therapy in systemic lupus erythematosus"],"prefix":"10.1111","volume":"13","author":[{"given":"Mo Yin","family":"MOK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,28]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.260"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.953"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh259"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2006.04.006"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1997.4353"},{"key":"e_1_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.7.4298"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2004.05.010"},{"key":"e_1_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4284"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008010112"},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.10.1639"},{"issue":"7","key":"e_1_2_14_12_2","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.4049\/jimmunol.163.7.3592","article-title":"B\u2010cells are required for lupus nephritis in the polygenic, Fas\u2010intact MRL model of systemic autoimmunity","volume":"163","author":"Chan OT","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.004"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.1.6"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23678"},{"key":"e_1_2_14_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215034"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022491"},{"key":"e_1_2_14_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018663"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4314"},{"key":"e_1_2_14_22_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090517"},{"key":"e_1_2_14_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x"},{"key":"e_1_2_14_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106174"},{"key":"e_1_2_14_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24341"},{"key":"e_1_2_14_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22211"},{"key":"e_1_2_14_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22505"},{"key":"e_1_2_14_28_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04030808"},{"key":"e_1_2_14_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20592"},{"key":"e_1_2_14_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20858"},{"key":"e_1_2_14_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.12.006"},{"key":"e_1_2_14_32_2","first-page":"S347","article-title":"Design and baseline characteristics of patients in randomized double blind placebo controlled phase I\/II study (EXPLORER) to evaluate the efficacy and safety of rituximab in patients with moderate to severely active systemic lupus erythematosus [Abstract]","volume":"67","author":"Merrill TJ","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"e_1_2_14_33_2","first-page":"1206","article-title":"Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B\u2010cell malignancies","volume":"9","author":"Hutas G","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_14_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.05.007"},{"key":"e_1_2_14_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075762"},{"key":"e_1_2_14_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1942"},{"key":"e_1_2_14_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699"},{"key":"e_1_2_14_38_2","first-page":"S2069","article-title":"Four\u2010year experience of belimumab, a BLyS\u2010specific inhibitor in systemic lupus erythematosus patients [Abstract]","volume":"60","author":"Petri MFR","year":"2009","journal-title":"Arthritis Rheum"},{"key":"e_1_2_14_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00425-9"},{"key":"e_1_2_14_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/35010115"},{"key":"e_1_2_14_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23047"},{"key":"e_1_2_14_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10763"},{"key":"e_1_2_14_43_2","unstructured":"DeyE.La Jolla stops developing lupus drug:shares tank. UPDATE 2;http:\/\/www.reuters.com\/article\/marketsNews\/."},{"issue":"5","key":"e_1_2_14_44_2","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4049\/jimmunol.160.5.2158","article-title":"Anti\u2010CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function","volume":"160","author":"Kalled SL","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_14_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10856"},{"key":"e_1_2_14_46_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.2913"},{"key":"e_1_2_14_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10764"},{"key":"e_1_2_14_48_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040168"},{"issue":"12","key":"e_1_2_14_49_2","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.4049\/jimmunol.138.12.4222","article-title":"Treatment with high doses of anti\u2010IgM prevents, but with lower doses accelerates autoimmune disease in (NZW x BXSB)F1 hybrid mice","volume":"138","author":"Cerny A","year":"1987","journal-title":"J Immunol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2009.01458.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2009.01458.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T23:10:26Z","timestamp":1698707426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2009.01458.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,28]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1756-185X.2009.01458.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2009.01458.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,28]]},"assertion":[{"value":"2010-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}